FMP
NeuroBo Pharmaceuticals, Inc.
NRBO
NASDAQ
Inactive Equity
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
2.36 USD
0 (0%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Mr. Hyung-Heon Kim
sector
Healthcare
industry
Biotechnology
exchange
NASDAQ
Description
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
CIK
0001638287
ISIN
US64132R4048
CUSIP
64132R107
Address
200 Berkeley Street
Phone
857 702 9600
Country
US
Employee
8
IPO Date
Aug 5, 2016
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
NRBO Financial Summary
CIK
0001638287
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
64132R107
ISIN
US64132R4048
Country
US
Price
2.36
Beta
-0.28
Volume Avg.
0
Market Cap
20.33M
Shares
-
52-Week
-
DCF
4.38
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.55
P/B
-
Website
https://www.neurobopharma.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest NRBO News
It looks like there's no news available.
